Evidence map›Paper›PMID 41587945›Full record

ArticleJournal of the National Cancer Institute2026

Weight trajectories throughout adulthood and prostate cancer incidence, aggressiveness, and death in 258 494 men.

Marisa da Silva, Josef Fritz, Ahmed Elhakeem, Sylvia H J Jochems, Ming Sun, Innocent B Mboya, Christel Häggström, Jens Wahlström, Karl Michaëlsson, Patrik K E Magnusson and 12 more

Abstract read
In one paragraph

Article in Journal of the National Cancer Institute, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

22 authors.

Marisa da SilvaDepartment of Translational Medicine, Lund University, Malmö, Sweden.ORCID 0000-0003-1215-8625
Josef FritzDepartment of Translational Medicine, Lund University, Malmö, Sweden.ORCID 0000-0003-1342-3435
Ahmed ElhakeemPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID 0000-0001-7637-6360
Sylvia H J JochemsInstitute for Risk Assessment Sciences, Utrecht University, Utrecht, The Netherlands.
Ming SunDepartment of Translational Medicine, Lund University, Malmö, Sweden.ORCID 0000-0002-4134-6935
Innocent B MboyaDepartment of Translational Medicine, Lund University, Malmö, Sweden.ORCID 0000-0001-9861-5879
Christel HäggströmNorthern Registry Centre, Department of Diagnostics and Intervention, Umeå University, Umeå, Sweden.ORCID 0000-0001-6808-4405
Jens WahlströmDepartment of Epidemiology and Global Health, Umeå University, Umeå, Sweden.ORCID 0000-0002-2359-509X
Karl MichaëlssonMedical Epidemiology, Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.ORCID 0000-0003-2815-1217
Patrik K E MagnussonDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-7315-7899
Ylva T LagerrosDepartment of Medicine, Huddinge, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-6816-7577
Lena LönnbergCentre for Clinical Research, Västmanland, Uppsala University, Västerås, Sweden.ORCID 0000-0003-4706-6915
Abbas ChabokDepartment of Clinical Sciences, Division of Surgery, Danderyd Hospital, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0001-9662-5045
Sölve ElmståhlDepartment of Clinical Sciences Malmö, Lund University, Malmö, Sweden.ORCID 0000-0001-7153-5414
Bright I NwaruKrefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0002-2876-6089
Hannu KankaanrantaKrefting Research Centre, Department of Internal Medicine and Clinical Nutrition, Institute of Medicine, Sahlgrenska Academy, University of Gothenburg, Gothenburg, Sweden.ORCID 0000-0001-5258-0906
Linnea HedmanDepartment of Public Health and Clinical Medicine, The OLIN and Sunderby Research Unit, Umeå University, Umeå, Sweden.ORCID 0000-0002-1630-3167
Helena BackmanDepartment of Public Health and Clinical Medicine, The OLIN and Sunderby Research Unit, Umeå University, Umeå, Sweden.ORCID 0000-0002-0553-8067
Sara HäggDepartment of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.ORCID 0000-0002-2452-1500
Pär StattinDepartment of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Kate TillingPopulation Health Sciences, Bristol Medical School, University of Bristol, Bristol, United Kingdom.ORCID 0000-0002-1010-8926
Tanja StocksDepartment of Translational Medicine, Lund University, Malmö, Sweden.ORCID 0000-0002-0904-0557

Funding

Cancer Research Foundation at the Department of Oncology, Malmö University HospitalCrafoord Foundation 20200546Mrs Berta Kamprad's Cancer Foundation FBKS-2021-12Swedish Cancer Society 20 1033 PjFSwedish Cancer Society 23 0633 SIASwedish Prostate Cancer FederationSwedish Research Council 2021-01934Wereld Kanker Onderzoek Fonds, as part of the World Cancer Research Fund International grant program IIG_FULL_2020_025
6 · The paper itself

Abstract

backgroundObesity assessed at a single time point in adulthood has shown no consistent association with prostate cancer (PCa) incidence but has been positively associated with PCa death. We investigated the association of total and age-specific adult weight trajectories with PCa aggressiveness and death.

methodsWe analyzed data from 258,494 men in Sweden with at least 3 weight observations between ages 17 and 60. Individual weight trajectories were estimated using linear mixed-effects models with natural cubic and linear splines for age, incorporating random intercepts and slopes. These estimates were included in multivariable-adjusted Cox proportional hazards models.

resultsOver a median follow-up of 25 years, 22 055 men were diagnosed with PCa and 4547 died from the disease. Steep weight gain was inversely associated with PCa diagnosed during the PSA testing era (1997 onwards) and via asymptomatic PSA testing, but not with aggressive PCa. Among men with PCa, steep weight gain was associated with increased risk of PCa death (HR quintile 5 vs. 1 = 1.23, 95% CI = 1.08 to 1.40), primarily driven by weight gain between ages 45 and 60 (HR per 1 kg/year = 1.31, 95% CI = 1.10 to 1.57).

conclusionsThe associations observed for incident PCa appear to be influenced by PSA testing uptake; however, the extent to which detection bias contributes remains uncertain. Conversely, late midlife weight gain was associated with an elevated risk of PCa death, underscoring the importance of weight management during this period as a potentially modifiable factor for reducing PCa death.

Indexed as

Body-Weight TrajectoryObesityProstatic NeoplasmsWeight GainAdolescentAdultBody Mass IndexFollow-Up StudiesHumansIncidenceMaleMiddle AgedProportional Hazards ModelsProstate-Specific AntigenRisk FactorsSwedenProstate-Specific Antigen

Identifiers

PMID41587945
PMCPMC13247337

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.